Citations (81)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Austin N. Spratt, Fabio Gallazzi, Thomas P. Quinn, Christian L. Lorson, Anders Sönnerborg & Kamal Singh. (2021) Coronavirus helicases: attractive and unique targets of antiviral drug-development and therapeutic patents. Expert Opinion on Therapeutic Patents 31:4, pages 339-350.
Read now
Read now
Beyza Dönmüş, Sinan Ünal, Fatma Ceren Kirmizitaş & Nelisa Türkoğlu Laçin. (2021) Virus-associated ribozymes and nano carriers against COVID-19. Artificial Cells, Nanomedicine, and Biotechnology 49:1, pages 204-218.
Read now
Read now
Kuldeep Dhama, Khan Sharun, Ruchi Tiwari, Maryam Dadar, Yashpal Singh Malik, Karam Pal Singh & Wanpen Chaicumpa. (2020) COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics. Human Vaccines & Immunotherapeutics 16:6, pages 1232-1238.
Read now
Read now
Amin Sadeghi Dousari, Majid Taati Moghadam & Naghmeh Satarzadeh. (2020) COVID-19 (Coronavirus Disease 2019): A New Coronavirus Disease. Infection and Drug Resistance 13, pages 2819-2828.
Read now
Read now
Articles from other publishers (77)
Han Bai, Liyuan Liang, Xin Qi, Yao Xu, Yijia Liu, Doudou Ren, Zeqiong Cai, Weikang Mao, Xiaorui Wang, Hongyu Qin, Fang Hu & Bingyin Shi. (2023) Thymosin α1 modulated the immune landscape of COVID-19 patients revealed by single-cell RNA and TCR sequencing. International Immunopharmacology 124, pages 110983.
Crossref
Crossref
Doha H. Abou Baker, Emad M. Hassan & Souad El Gengaihi. (2023) An overview on medicinal plants used for combating coronavirus: Current potentials and challenges. Journal of Agriculture and Food Research 13, pages 100632.
Crossref
Crossref
Sk Injamamul Islam, Sheikh Sunzid Ahmed, Nasim Habib, Md Akib Ferdous, Saloa Sanjida & Moslema Jahan Mou. (2023) High-throughput virtual screening of marine algae metabolites as high-affinity inhibitors of ISKNV major capsid protein: An analysis of in-silico models and DFT calculation to find novel drug molecules for fighting infectious spleen and kidney necrosis virus (ISKNV). Heliyon 9:6, pages e16383.
Crossref
Crossref
Babita Sarangi, Jyotirmaya Sahoo, Utpal Jana & Guru P. Mohanta. (2023) CORONAVIRUS DISEASE 2019 (COVID-19): PUBLIC HEALTH EMERGENCY. Indian Drugs 60:05, pages 7-21.
Crossref
Crossref
Sk Injamamul Islam, M. Norjit Singh, C. Sonia, Md Akib Ferdous, Nasim Habib, Saloa Sanjida, Md Jamadul Islam, Nahidul Islam & Mohamed H Hamad. (2023) Ligand-based Virtual Screening, Quantum Mechanics Calculations, and Normal Mode Analysis of Phytochemical Compounds Targeting Toll‐Interacting Protein (Tollip) Against Bacterial Diseases. Toxicology International, pages 139-153.
Crossref
Crossref
Sayed Sartaj Sohrab, Sherif Aly El-Kafrawy, Zeenat Mirza, Ahmed M. Hassan, Fatima Alsaqaf & Esam Ibraheem Azhar. (2023) Delivery of siRNAs against MERS-CoV in Vero and HEK-293 cells: A comparative evaluation of transfection reagents. Journal of King Saud University - Science 35:3, pages 102540.
Crossref
Crossref
Ajay Manaithiya, Ozair Alam, Shruti Mittal, Mohd. Javed Naim, Mohd. Imran, Ahmed Subeh Alshrari, Aadil A. Sheikh & Imran A. Khan. (2023) An Updated and Focused Review on Heterocyclic Inhibitors for SARSCoV
and SARS-CoV-2 3CLpro. Mini-Reviews in Medicinal Chemistry 23:5, pages 576-632.
Crossref
Crossref
Sayed S. Sohrab, Sherif A. El-Kafrawy, Zeenat Mirza, Ahmed M. Hassan, Fatima Alsaqaf & Esam I. Azhar. (2023) Computational Design and Experimental Evaluation of MERS-CoV siRNAs in Selected Cell Lines. Diagnostics 13:1, pages 151.
Crossref
Crossref
Srirupa Bhattacharyya, Kajal Sandhu & S Chockalingam. 2023. Emerging Nanotechnologies for Medical Applications. Emerging Nanotechnologies for Medical Applications
273
296
.
R. Jegan, P. Rajalakshmy, P. Subha Hency Jose & W. S. Nimi. (2021) 2019-nCoV effects, transmission and preventive measures: an overview. Journal of Public Health 31:1, pages 27-35.
Crossref
Crossref
Anna Mary Jose. (2022) Analyzing the Impermeable Structure and Myriad of Antiviral Therapies for SARS-CoV-2. Journal of the Association of Physicians of India 70:11, pages 80-84.
Crossref
Crossref
Seham S. El-hawary, Taha F. S. Ali, Sara O. Abo El-Ela, Ahlam Elwekeel, Usama Ramadan Abdelmohsen & Asmaa I. Owis. (2022)
Secondary metabolites of
Livistona decipiens
as potential inhibitors of SARS-CoV-2
. RSC Advances 12:30, pages 19505-19511.
Crossref
Crossref
Atanu BhattacharjeeNongmaithem Randhoni ChanuKunal Bhattacharya. (2022) COVID-19 Pandemic: A Pragmatic plan for Therapeutic Intervention. Research Journal of Pharmacy and Technology, pages 2862-2868.
Crossref
Crossref
Seyedeh Hoda Alavizadeh, Maham Doagooyan, Fatemeh Zahedipour, Shima Yahoo Torghabe, Bahare Baharieh, Firooze Soleymani & Fatemeh Gheybi. (2022) Antisense technology as a potential strategy for the treatment of coronaviruses infection: With focus on COVID‐19. IET Nanobiotechnology 16:3, pages 67-77.
Crossref
Crossref
Md. Mominur Rahman, Muniruddin Ahmed, Mohammad Touhidul Islam, Md. Robin Khan, Sharifa Sultana, Saila Kabir Maeesa, Sakib Hasan, Md. Abid Hossain, Kazi Sayma Ferdous, Bijo Mathew, Abdur Rauf & Md. Sahab Uddin. (2022) Nanotechnology-based Approaches and Investigational Therapeutics against
COVID-19. Current Pharmaceutical Design 28:12, pages 948-968.
Crossref
Crossref
Maxim S. Kupryushkin, Anton V. Filatov, Nadezhda L. Mironova, Olga A. Patutina, Ivan V. Chernikov, Elena L. Chernolovskaya, Marina A. Zenkova, Dmitrii V. Pyshnyi, Dmitry A. Stetsenko, Sidney Altman & Valentin V. Vlassov. (2022) Antisense oligonucleotide gapmers containing phosphoryl guanidine groups reverse MDR1-mediated multiple drug resistance of tumor cells. Molecular Therapy - Nucleic Acids 27, pages 211-226.
Crossref
Crossref
Moutoshi Chakraborty & SaurabKishore Munshi. (2022) The prospects of employing probiotics in combating COVID-19. Tzu Chi Medical Journal 34:2, pages 148.
Crossref
Crossref
Mahendra K. Verma, Yogendra Kumar Verma & M.V. Raghavendra Rao. 2022. Nanotechnological Applications in Virology. Nanotechnological Applications in Virology
235
252
.
Kaifu Gao, Rui Wang, Jiahui Chen, Jetze J. Tepe, Faqing Huang & Guo-Wei Wei. (2021) Perspectives on SARS-CoV-2 Main Protease Inhibitors. Journal of Medicinal Chemistry 64:23, pages 16922-16955.
Crossref
Crossref
Syed Mohammed Basheeruddin Asdaq, Syed Imam Rabbani, Meshary Alkahtani, Meshal Meshary Aldohyan, Abdullah Mohammad Alabdulsalam, Majed Sadun Alshammari, Saleh Ahmad Alajlan, Aljawharah Binrokan, Yahya Mohzari, Ahmed Alrashed, Mohammed Kanan Alshammari, Mohd. Imran & Naira Nayeem. (2021) A Patent Review on the Therapeutic Application of Monoclonal Antibodies in COVID-19. International Journal of Molecular Sciences 22:21, pages 11953.
Crossref
Crossref
Palas Samanta & Apurba Ratan Ghosh. (2021) Environmental perspectives of COVID-19 outbreaks: A review. World Journal of Gastroenterology 27:35, pages 5822-5850.
Crossref
Crossref
Huihui Yang & Jinfei Yang. (2021)
A review of the latest research on M
pro
targeting SARS-COV inhibitors
. RSC Medicinal Chemistry 12:7, pages 1026-1036.
Crossref
Crossref
Seyed Abdulmajid Ayatollahi, Javad Sharifi-Rad, Patrick Valere Tsouh Fokou, Gail B. Mahady, Hafiz Ansar Rasul Suleria, Shivani Krishna Kapuganti, Kundlik Gadhave, Rajanish Giri, Neha Garg, Rohit Sharma, Daniel Ribeiro, Célia F. Rodrigues, Željko Reiner, Yasaman Taheri & Natália Cruz-Martins. (2021) Naturally Occurring Bioactives as Antivirals: Emphasis on Coronavirus Infection. Frontiers in Pharmacology 12.
Crossref
Crossref
Burak Berber, Cihan Aydin, Fatih Kocabas, Gulen Guney-Esken, Kaan Yilancioglu, Medine Karadag-Alpaslan, Mehmet Caliseki, Melek Yuce, Sevda Demir & Cihan Tastan. (2020) Gene editing and RNAi approaches for COVID-19 diagnostics and therapeutics. Gene Therapy 28:6, pages 290-305.
Crossref
Crossref
Shaden A.M. Khalifa, Nermeen Yosri, Mohamed F. El-Mallah, Reem Ghonaim, Zhiming Guo, Syed Ghulam Musharraf, Ming Du, Alfi Khatib, Jianbo Xiao, Aamer Saeed, Haged H.R. El-Seedi, Chao Zhao, Thomas Efferth & Hesham R. El-Seedi. (2021) Screening for natural and derived bio-active compounds in preclinical and clinical studies: One of the frontlines of fighting the coronaviruses pandemic. Phytomedicine 85, pages 153311.
Crossref
Crossref
Amiya Das, Deepti Pandita, Gaurav Kumar Jain, Pallavi Agarwal, Ajmer Singh Grewal, Roop K. Khar & Viney Lather. (2021) Role of phytoconstituents in the management of COVID-19. Chemico-Biological Interactions 341, pages 109449.
Crossref
Crossref
Sherif Aly El-Kafrawy, Sayed Sartaj Sohrab, Zeenat Mirza, Ahmed M. Hassan, Fatima Alsaqaf & Esam Ibraheem Azhar. (2021) In Vitro Inhibitory Analysis of Rationally Designed siRNAs against MERS-CoV Replication in Huh7 Cells. Molecules 26:9, pages 2610.
Crossref
Crossref
Inácio Gomes Medeiros, André Salim Khayat, Beatriz Stransky, Sidney Santos, Paulo Assumpção & Jorge Estefano Santana de Souza. (2021) A small interfering RNA (siRNA) database for SARS-CoV-2. Scientific Reports 11:1.
Crossref
Crossref
Asmaa I. Owis, Marwa S. El-Hawary, Dalia El Amir, Hesham Refaat, Eman Alaaeldin, Omar M. Aly, Mahmoud A. Elrehany & Mohamed S. Kamel. (2021)
Flavonoids of
Salvadora persica
L. (meswak) and its liposomal formulation as a potential inhibitor of SARS-CoV-2
. RSC Advances 11:22, pages 13537-13544.
Crossref
Crossref
Raviteja Chemboli, Ravikumar Kapavarapu, K. Deepti, K.R.S. Prasad, Alugubelli Gopi Reddy, A. V. D. Nagendra Kumar, Mandava Venkata Basaveswara Rao & Manojit Pal. (2021) Pyrrolo[2,3-b]quinoxalines in attenuating cytokine storm in COVID-19: their sonochemical synthesis and in silico / in vitro assessment. Journal of Molecular Structure 1230, pages 129868.
Crossref
Crossref
Salar Hafez Ghoran, Mohamed El-Shazly, Nazim Sekeroglu & Anake Kijjoa. (2021) Natural Products from Medicinal Plants with Anti-Human Coronavirus Activities. Molecules 26:6, pages 1754.
Crossref
Crossref
J. Wes Ulm & Stanley F. Nelson. (2020) COVID‐19 drug repurposing: Summary statistics on current clinical trials and promising untested candidates. Transboundary and Emerging Diseases 68:2, pages 313-317.
Crossref
Crossref
Surya Goel & Ram Dayal. (2021) Novel Corona-Virus Disease 2019 (COVID-19): A Perilous Life- Threatening Epidemic. Coronaviruses 2:2, pages 215-222.
Crossref
Crossref
Sayed Sartaj Sohrab, Sherif Aly El-Kafrawy, Zeenat Mirza, Ahmed M. Hassan, Fatima Alsaqaf & Esam Ibraheem Azhar. (2021) In silico prediction and experimental validation of siRNAs targeting ORF1ab of MERS-CoV in Vero cell line. Saudi Journal of Biological Sciences 28:2, pages 1348-1355.
Crossref
Crossref
Sayed Sartaj Sohrab, Sherif Aly El-Kafrawy, Zeenat Mirza, Ahmed M. Hassan, Fatima Alsaqaf & Esam Ibraheem Azhar. (2021) Designing and evaluation of MERS-CoV siRNAs in HEK-293 cell line. Journal of Infection and Public Health 14:2, pages 238-243.
Crossref
Crossref
Arghyadeep Bhattacharjee, Manish Saha, Arpita Halder, Arka Debnath & Oindrilla Mukherjee. (2021) Therapeutics and Vaccines: Strengthening Our Fight Against the Global Pandemic COVID-19. Current Microbiology 78:2, pages 435-448.
Crossref
Crossref
Figen Sarigul Yildirim, Murat Sayan, Tamer Sanlidag, Berna Uzun, Dilber Uzun Ozsahin & Ilker Ozsahin. (2021) Comparative Evaluation of the Treatment of COVID-19 with Multicriteria Decision-Making Techniques. Journal of Healthcare Engineering 2021, pages 1-11.
Crossref
Crossref
Konstantina Vougogiannopoulou, Angela Corona, Enzo Tramontano, Michael N. Alexis & Alexios-Leandros Skaltsounis. (2021) Natural and Nature-Derived Products Targeting Human Coronaviruses. Molecules 26:2, pages 448.
Crossref
Crossref
Zemene Demelash Kifle, Engidaw Fentahun Enyew & Abebe Basazn Mekuria. (2021) A Recent Achievement in the Discovery and Development of Vaccines and Therapeutic Agents in the Race for COVID-19 Protection and Treatment. Journal of Evidence-Based Integrative Medicine 26, pages 2515690X2110037.
Crossref
Crossref
Claudia Matteucci, Antonella Minutolo, Emanuela Balestrieri, Vita Petrone, Marialaura Fanelli, Vincenzo Malagnino, Marco Ianetta, Alessandro Giovinazzo, Filippo Barreca, Silvia Di Cesare, Patrizia De Marco, Martino Tony Miele, Nicola Toschi, Antonio Mastino, Paola Sinibaldi Vallebona, Sergio Bernardini, Paola Rogliani, Loredana Sarmati, Massimo Andreoni, Sandro Grelli & Enrico Garaci. (2021) Thymosin Alpha 1 Mitigates Cytokine Storm in Blood Cells From Coronavirus Disease 2019 Patients. Open Forum Infectious Diseases 8:1.
Crossref
Crossref
Pratibha Gupta. (2021) A review: Epidemiology, pathogenesis and prospect in developing vaccines for novel Coronavirus (COVID-19). Indian Journal of Tuberculosis 68:1, pages 92-98.
Crossref
Crossref
Thanigaimalai Pillaiyar, Lukas L. Wendt, Manoj Manickam & Maheswaran Easwaran. (2020) The recent outbreaks of human coronaviruses: A medicinal chemistry perspective. Medicinal Research Reviews 41:1, pages 72-135.
Crossref
Crossref
Elmas Pınar KAHRAMAN & Mustafa ALTINDİŞ. (2020) COVID-19 Aşıları; Pandemide Sona Doğru?COVID 19 Vaccines; Towards The end of The Pandemic?. Journal of Biotechnology and Strategic Health Research 4:3, pages 240-249.
Crossref
Crossref
Laura Teodori, Piero Sestili, Valeria Madiai, Sofia Coppari, Daniele Fraternale, Marco Bruno Luigi Rocchi, Seeram Ramakrishna & Maria Cristina Albertini. (2020) MicroRNAs Bioinformatics Analyses Identifying HDAC Pathway as a Putative Target for Existing Anti‐COVID‐19 Therapeutics. Frontiers in Pharmacology 11.
Crossref
Crossref
Ankit Kumar Dubey, Aakansha Singh, Shardendu Prakash, Manoj Kumar & Ashok K Singh. (2020) Race to arsenal COVID-19 therapeutics: Current alarming status and future directions. Chemico-Biological Interactions 332, pages 109298.
Crossref
Crossref
Zainab Sarwar, Tahir Ahmad & Salik Kakar. (2020) Potential approaches to combat COVID-19: a mini-review. Molecular Biology Reports 47:12, pages 9939-9949.
Crossref
Crossref
Duc Duy Nguyen, Kaifu Gao, Jiahui Chen, Rui Wang & Guo-Wei Wei. (2020) Unveiling the molecular mechanism of SARS-CoV-2 main protease inhibition from 137 crystal structures using algebraic topology and deep learning. Chemical Science 11:44, pages 12036-12046.
Crossref
Crossref
Akshay Kanakan, Neha Mishra, Janani Srinivasa Vasudevan, Shweta Sahni, Azka Khan, Sachin Sharma & Rajesh Pandey. (2020) Threading the Pieces Together: Integrative Perspective on SARS-CoV-2. Pathogens 9:11, pages 912.
Crossref
Crossref
Md. Farhad Hossain, Sharifa Hasana, Abdullah Al Mamun, Md. Sahab Uddin, Mir Imam Ibne Wahed, Sabarni Sarker, Tapan Behl, Irfan Ullah, Yesmin Begum, Israt Jahan Bulbul, Md. Shah Amran, Md. Habibur Rahman, May N. Bin-Jumah, Saad Alkahtani, Shaker A. Mousa, Lotfi Aleya & Mohamed M. Abdel-Daim. (2020) COVID-19 Outbreak: Pathogenesis, Current Therapies, and Potentials for Future Management. Frontiers in Pharmacology 11.
Crossref
Crossref
Daniel Chakhalian, Robert B. Shultz, Catherine E. Miles & Joachim Kohn. (2020)
Opportunities for biomaterials to address the challenges of
COVID
‐19
. Journal of Biomedical Materials Research Part A 108:10, pages 1974-1990.
Crossref
Crossref
Kuldeep Dhama, Sharun Khan, Ruchi Tiwari, Shubhankar Sircar, Sudipta Bhat, Yashpal Singh Malik, Karam Pal Singh, Wanpen Chaicumpa, D. Katterine Bonilla-Aldana & Alfonso J. Rodriguez-Morales. (2020) Coronavirus Disease 2019–COVID-19. Clinical Microbiology Reviews 33:4.
Crossref
Crossref
Kuan-Hsuan Chen, Sheng-Fan Wang, Szu-Yu Wang, Yi-Ping Yang, Mong-Lien Wang, Sih-Hwa Chiou & Yuh-Lih Chang. (2020) Pharmacological development of the potential adjuvant therapeutic agents against coronavirus disease 2019. Journal of the Chinese Medical Association 83:9, pages 817-821.
Crossref
Crossref
Ehsaneh Khodadadi, Parham Maroufi, Ehsan Khodadadi, Isabella Esposito, Khudaverdi Ganbarov, Silvano Espsoito, Mehdi Yousefi, Elham Zeinalzadeh & Hossein Samadi Kafil. (2020) Study of combining virtual screening and antiviral treatments of the Sars-CoV-2 (Covid-19). Microbial Pathogenesis 146, pages 104241.
Crossref
Crossref
Kirtikumar C. Badgujar, Vivek C. Badgujar & Shamkant B. Badgujar. (2020) Vaccine development against coronavirus (2003 to present): An overview, recent advances, current scenario, opportunities and challenges. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 14:5, pages 1361-1376.
Crossref
Crossref
David C. Fajgenbaum, Johnson S. Khor, Alexander Gorzewski, Mark-Avery Tamakloe, Victoria Powers, Joseph J. Kakkis, Mileva Repasky, Anne Taylor, Alexander Beschloss, Laura Hernandez-Miyares, Beatrice Go, Vivek Nimgaonkar, Madison S. McCarthy, Casey J. Kim, Ruth-Anne Langan Pai, Sarah Frankl, Philip Angelides, Joanna Jiang, Rozena Rasheed, Erin Napier, Duncan Mackay & Sheila K. Pierson. (2020) Treatments Administered to the First 9152 Reported Cases of COVID-19: A Systematic Review. Infectious Diseases and Therapy 9:3, pages 435-449.
Crossref
Crossref
Helena F. Florindo, Ron Kleiner, Daniella Vaskovich-Koubi, Rita C. Acúrcio, Barbara Carreira, Eilam Yeini, Galia Tiram, Yulia Liubomirski & Ronit Satchi-Fainaro. (2020) Immune-mediated approaches against COVID-19. Nature Nanotechnology 15:8, pages 630-645.
Crossref
Crossref
Vaibhav Tiwari, Jacob C. Beer, Nehru Viji Sankaranarayanan, Michelle Swanson-Mungerson & Umesh R. Desai. (2020) Discovering small-molecule therapeutics against SARS-CoV-2. Drug Discovery Today 25:8, pages 1535-1544.
Crossref
Crossref
Alessandra Fierabracci, Andrea Arena & Paolo Rossi. (2020) COVID-19: A Review on Diagnosis, Treatment, and Prophylaxis. International Journal of Molecular Sciences 21:14, pages 5145.
Crossref
Crossref
Karun Neupane, Zahoor Ahmed, Hira Pervez, Rabia Ashraf & Aneela Majeed. (2020) Potential Treatment Options for COVID-19: A Comprehensive Review of Global Pharmacological Development Efforts. Cureus.
Crossref
Crossref
Ananda da Silva Antonio, Larissa Silveira Moreira Wiedemann & Valdir Florêncio Veiga-Junior. (2020) Natural products' role against COVID-19. RSC Advances 10:39, pages 23379-23393.
Crossref
Crossref
Luigina Romani, Carlo Tomino, Paolo Puccetti & Enrico Garaci. (2020) Off-label therapy targeting pathogenic inflammation in COVID-19. Cell Death Discovery 6:1.
Crossref
Crossref
Arun K. Ghosh, Margherita Brindisi, Dana Shahabi, Mackenzie E. Chapman & Andrew D. Mesecar. (2020) Drug Development and Medicinal Chemistry Efforts toward SARS‐Coronavirus and Covid‐19 Therapeutics. ChemMedChem 15:11, pages 907-932.
Crossref
Crossref
Lisheng Wang, Yiru Wang, Dawei Ye & Qingquan Liu. (2020) Review of the 2019 novel coronavirus (SARS-CoV-2) based on current evidence. International Journal of Antimicrobial Agents 55:6, pages 105948.
Crossref
Crossref
James C. Crosby, Matthew A. Heimann, Samuel L. Burleson, Brendan C. Anzalone, Jonathan F. Swanson, Douglas W. Wallace & Christopher J. Greene. (2020) COVID‐19: A review of therapeutics under investigation. Journal of the American College of Emergency Physicians Open 1:3, pages 231-237.
Crossref
Crossref
Ahmed M. Sayed, Amira R. Khattab, Asmaa M. AboulMagd, Hossam M. Hassan, Mostafa E. Rateb, Hala Zaid & Usama Ramadan Abdelmohsen. (2020) Nature as a treasure trove of potential anti-SARS-CoV drug leads: a structural/mechanistic rationale. RSC Advances 10:34, pages 19790-19802.
Crossref
Crossref
Mona Fani, Ali Teimoori & Shokouh Ghafari. (2020) Comparison of the COVID-2019 (SARS-CoV-2) pathogenesis with SARS-CoV and MERS-CoV infections. Future Virology 15:5, pages 317-323.
Crossref
Crossref
Lei Zhang & Yunhui Liu. (2020) Potential interventions for novel coronavirus in China: A systematic review. Journal of Medical Virology 92:5, pages 479-490.
Crossref
Crossref
Krishani Dinali Perera, Anushka C. Galasiti Kankanamalage, Athri D. Rathnayake, Amanda Honeyfield, William Groutas, Kyeong-Ok Chang & Yunjeong Kim. (2018) Protease inhibitors broadly effective against feline, ferret and mink coronaviruses. Antiviral Research 160, pages 79-86.
Crossref
Crossref
Kevin Watkins. (2018) Emerging Infectious Diseases: a Review. Current Emergency and Hospital Medicine Reports 6:3, pages 86-93.
Crossref
Crossref
Ali A. Rabaan, Ali M. Bazzi, Shamsah H. Al-Ahmed & Jaffar A. Al-Tawfiq. (2017) Molecular aspects of MERS-CoV. Frontiers of Medicine 11:3, pages 365-377.
Crossref
Crossref
Vathan Kumar, Jin Soo Shin, Jiun-Jie Shie, Keun Bon Ku, Chonsaeng Kim, Yun Young Go, Kai-Fa Huang, Meehyein Kim & Po-Huang Liang. (2017) Identification and evaluation of potent Middle East respiratory syndrome coronavirus (MERS-CoV) 3CL Pro inhibitors. Antiviral Research 141, pages 101-106.
Crossref
Crossref
Qihui Wang, Gary Wong, Guangwen Lu, Jinghua Yan & George F. Gao. (2016) MERS-CoV spike protein: Targets for vaccines and therapeutics. Antiviral Research 133, pages 165-177.
Crossref
Crossref
Vathan Kumar, Kian-Pin Tan, Ying-Ming Wang, Sheng-Wei Lin & Po-Huang Liang. (2016) Identification, synthesis and evaluation of SARS-CoV and MERS-CoV 3C-like protease inhibitors. Bioorganic & Medicinal Chemistry 24:13, pages 3035-3042.
Crossref
Crossref
Kayvon Modjarrad. (2016) MERS-CoV vaccine candidates in development: The current landscape. Vaccine 34:26, pages 2982-2987.
Crossref
Crossref
Yunjeong Kim, Hongwei Liu, Anushka C. Galasiti Kankanamalage, Sahani Weerasekara, Duy H. Hua, William C. Groutas, Kyeong-Ok Chang & Niels C. Pedersen. (2016) Reversal of the Progression of Fatal Coronavirus Infection in Cats by a Broad-Spectrum Coronavirus Protease Inhibitor. PLOS Pathogens 12:3, pages e1005531.
Crossref
Crossref
Mukesh Mahajan & Surajit Bhattacharjya. (2015) NMR structures and localization of the potential fusion peptides and the pre-transmembrane region of SARS-CoV: Implications in membrane fusion. Biochimica et Biophysica Acta (BBA) - Biomembranes 1848:2, pages 721-730.
Crossref
Crossref
Chia-Hsin Wu, Pei-Jer Chen & Shiou-Hwei Yeh. (2014) Nucleocapsid Phosphorylation and RNA Helicase DDX1 Recruitment Enables Coronavirus Transition from Discontinuous to Continuous Transcription. Cell Host & Microbe 16:4, pages 462-472.
Crossref
Crossref